Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 52, 2022 - Issue 5
237
Views
6
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Preclinical pharmacokinetics, CYP phenotyping, and tissue distribution study of novel anti-breast cancer candidate S-011-1559

, , , , , , , , , & show all
Pages 476-487 | Received 08 Jun 2022, Accepted 09 Jul 2022, Published online: 21 Jul 2022

References

  • Bhateria M, Ramakrishna R, Kumar Puttrevu S, Saxena AK, Bhatta RS. 2016. Enantioselective inhibition of cytochrome p450-mediated drug metabolism by a novel antithrombotic agent, S002-333: major effect on CYP2B6. Chem Biol Interact. 256:257–265.
  • Bohnert T, Gan L-S. 2013. Plasma protein binding: from discovery to development. J Pharm Sci. 102(9):2953–2994.
  • Chandasana H, Chhonker YS, Laxman TS, Prasad YD, Anil Kumar KS, Dikshit DK, Bhatta RS. 2016. Assessment of the pharmacokinetics, tissue distribution and excretion studies of a novel antiplatelet agent S007-867, following administration to rats. Drug Test Anal. 8(7):723–2729.
  • Gabrielsson J, Weiner D. 2001. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. US: CRC Press.
  • Ghosh A, Sarkar S, Banerjee S, Behbod F, Tawfik O, McGregor D, Graff S, Banerjee SK. 2018. MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis. PLoS One. 13(5):e0198143–23.
  • Giuliano C, Jairaj M, Zafiu CM, Laufer R. 2005. Direct determination of unbound intrinsic drug clearance in the microsomal stability assay. Drug Metab Dispos. 33(9):1319–1324.
  • Guan X. 2015. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 5(5):402–418.
  • Ingelman-Sundberg M. 2005. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1):6–13.
  • Jana AK, Singh J, Ganesher A, Kumar A, Banerjee A, Kumar D, Verma SK, Sharma AK, Bhatta RS, Konwar R, et al. 2021. Tyrosine-derived novel benzoxazine active in a rat syngenic mammary tumor model of breast cancer. J Med Chem. 64(21):16293–16316.
  • Jin X, Mu P. 2015. Targeting breast cancer metastasis. Breast Cancer. 9(Suppl 1):23–34.
  • Johanson G, McQueen CA. 2010. Comprehensive Toxicology. Amsterdam: Elsevier.
  • Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, Shin JG. 2005. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 19(18):2651–2658.
  • Masoud V, Pagès G. 2017. Targeted therapies in breast cancer: new challenges to fight against resistance. World J Clin Oncol. 8(2):120–134.
  • Meesters R, Voswinkel S. 2018. Bioanalytical method development and validation: from the USFDA 2001 to the USFDA 2018 guidance for industry. J Appl Bioanal. 4(3):67–73.
  • Merlot AM, Kalinowski DS, Richardson DR. 2014. Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol. 5:299.
  • Momenimovahed Z, Salehiniya H. 2019. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer. 11:151–164.
  • Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Macintyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 283(1):46–58.
  • Qian K, Rodgers RP, Hendrickson CL, Emmett MR, Marshall AG. 2001. Reading chemical fine print: resolution and identification of 3000 nitrogen-containing aromatic compounds from a single electrospray ionization Fourier transform ion cyclotron resonance mass spectrum of heavy petroleum crude oil. Energy & Fuels. 15(2):492–498.
  • Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. 2005. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 65(4):1459–1470.
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 71(3):209–249.
  • Taylor S, Harker A. 2006. Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal. 41(1):299–303.
  • Yu S, Li S, Yang H, Lee F, Wu JT, Qian MG. 2005. A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom. 19(2):250–5254.
  • Zhivkova Z. 2015. Studies on drug – human serum albumin binding: the current state of the matter. Curr Pharm Des. 21(14):1817–1830.
  • Zhou Y, Wu F, Li L, Shen X, Chen G, Wang X, Liang X, Tan M, Huang Z. 2020. Computational approaches in preclinical studies on drug discovery and development. Front Chem. 8(8):726–731.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.